Objective:To compare maternal serum levels of total activin A and inhibin A in preterm and tem patients who are in labor or not in laboar.
Methods:A cross-sectional study compared activin A and inhibin A in the following groups of patients: preterm and in labour (n = 65), preterm and not in labor (n = 96), term and in labor (n = 65), and term and not in labor (n = 65). Preterm was defined as 23-34 weeks' gestation and term as 37-43 weeks' gestation. Lobor was defined as regular contractions with progressive cervical change or an initial examination revealing cervical dilation of 1-3 cm with 50% effacement or more. Follistatin levbels were analyzed in a subset of 12 patients from each group. Analytes were measured by two-site enzyme-linked immunosorbent assays.
Results:Activin A levels were higher in the preterm labor group (median 1.38 multiples of the median [MoM], interquartile range [IQR] 1.01 MoM) compared with the preterm nonlabor group (median 1.0 MoM, IQR 0.78 MoM, P < .05) and in the term labor group (median 1.37 MoM, IQR 1.74 MoM) compared with the term nonlabor group (median 1.0 MoM, IQR 0.87 MoM, P < .05). Inhibin A levels were higher in the preterm labor group (median 1.27 MoM, IQR 0.73 MoM) compared with the preterm nonlabaor group (median 1.0 MoM, IQR 0.58 MoM, P < .05). Post-hoc analysis of activin A andinhibin A elevations in the preterm labor group revealed a significant effect only during 31-34 weeks' gestation. The total activin A:follistatin ratio, an indirect measure of free activin A, was similar between labor and nonlabor gestational age-matched patient groups.
Conclusions:Levels of total activin A and inhibin A were increased in patients during labor; however, based on the moderate degree and narror gestational age range of the increased levels, these analytes are not likely to be clinically useful in predicting preterm labor.
1. Andrews WW, Goldenberg RL, Hauth JC. Preterm labor: Emerging role of genital tract infections. Infect Agents Dis1995;4:196-211.
2.
2. Copper RL, Goldenberg RL, Creasy RK, et al. A multicenter study of preterm birth weight and gestational age-specific neonatal mortality. Am J Obstet Gynecol1993; 168:78-83.
3.
3. Taylor D. Low birthweight and neuro-developmental handicap. Clin Obstet Gynecol1984; 11:525-542.
4.
4. Jackson M, Dudley DJ. Endocrine assay to predict preterm delivery. Clin Perinatol1998;25:837-857.
5.
5. Lockwood CJ, Senyei AE, Dische MR, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med1991;325:669-674.
6.
6. Ying SY. Inhibins, activins and follistatin: Gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocr Rev1988;9:267-293.
7.
7. Wallace EM, Healy DL. Inhibins and activins: Role in clinical practice. Br J Obstet Gynaecol1996;103:945-956.
8.
8. Nakamura T, Takio K, Eto Y, Shibai H, Titani K, Sugino H. ACtivin-binding protein from rat ovary is follistatin. Science1990;247:836-838.
9.
9. Petraglia F. Inhibin, activin, and follistatin in the human placenta—a new family of regulatory proteins. Placenta1997;18:3-8.
10.
10. Petraglia F, Garg S, Florio P, et al. Activin A and activin B measured in maternal serum, cord blood serum and amniotic fluid during human pregnancy. Endocr J1993;1:323-327.
11.
11. Petraglia F, De Vita D, Gallinelli A, et al. Abnormal concentration of materanl serum activin A in gestatioanl diseases. J Clin Endocrinol Metab1995;80:558-561.
12.
12. Fowler PA, Evans LW, Groome NP, Templeton A, Knight PG. A longitudinal study of materanl serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-αC and follistatin during pregnancy. Hum Reprod1998;13:3530-3536.
13.
13. Schneider-Kolsky M, D'Antona D, Evans LW, et al. Maternal serum total activin A and follistatin in pregnancy and parturition. Br J Obstet Gynecol2000;107:995-1000.
14.
14. Woodruff TK, Sluss P, Wang E, Janssen I, Mersol-Barg MS. Activin A and follistatin are dynamically regulated during human pregnancy. J Endocrinol1997;152:167-174.
15.
15. Muttukrishna S, Fowler PA, George L, Groome NP, Knight PG. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy. J Clin Endocrinol Metab1996;81:3328-3334.
16.
16. O'Connor AE, McFarlane JR, Hayward S, Yohkaichiya T, Groome NP, de Kretser DM. Serum activin A and follistatin concentrations during human pregnancy: A cross-sectional and longitudinal study. Hum Reprod1999;14:827-832.
17.
17. Wakatsuki M, Shintani Y, Abe M, Liu ZH, Shitsukawa K, Saito S. Immunoradiometric assay for follistatin: Serum immunoreactive follistatin levels in normal adults and pregnant women. J Clin Endocrinol Metab1996;81:630-634.
18.
18. Petraglia F, Anceschi MM, Calza L, et al. Inhibin and activin in human fetal membranes: Evidence for a local effect on prosta-glandin release. J Clin Endocrinol Metab1993;77:542-548.
19.
19. Florio P, Lombardo M, Gallo R, et al. Activin A, corticotrophin-releasing factor, and prostaglandin F2α increase immunoreactive oxytocin release from cultured human placental cells. Placenta1996;17:307-311.
20.
20. Keelan JA, Zhou RL, Mitchell MD. Activin A exerts both proand anti-inflammatory effects on human term gestational tissues. Placenta2000;21:38-43.
21.
21. Keelan JA, Groome NP, Mitchell MD. Regulation of activin-A production by human amnion, deciduas and placenta in vitro bypro-inflammatory cytokines. Placenta1998;19:429-434.
22.
22. Keelan JA, Zhou RL, Evans LW, Groome NP, Mitchell MD. Regulation of activin A, inhibin A, and follistatin production in human amnion and choriodecidual explants by inflammatory mediators. J Soc Gynecol Investig2000;7:291-296.
23.
23. PEtraglia F, Gallinelli A, De Vita D, Lewis K, Mathews L, Vale W. Activin at parturition: Changes of maternal serum levels and evidence for binding sites in placenta and fetal membranes. Obstet Gynecol1994;84:278-282.
24.
24. Florio P, Benedetto C, Luisi S, et al. Activin A, inhibin A, inhibin B, and parturition: Changes of maternal and cord serum levels according to the mode of delivery. Br J Obstet Gynecol1999;106:1061-1065.
25.
25. Gallinelli A, Gallo R, Genazzani AD, et al. Episodic secretion of activin A in pregnant women. Eur J Endocrinol1996;135:340-344.
26.
26. D'Antona D, O'Connor A, Taylor N, Groome NP, de Kretser D, Wallace EM, Activin A levels in late pregnancy and labour (Abstract). J Soc Gynecol Investig1998;5:94A-94A.
27.
27. Coleman MAG, Grance JT, Schellenberg JC, et al. Corticotropin-releasing hormone, corticotropin-releasing hormone-binding protein, and activin A in maternal serum: Prediction of preterm delivery and response to glucocrticoids in women with symptoms of preterm labor. Am J Obstet Gynecol2000;183:643-648.
28.
28. Schneider-Kolsky M, Tong S, Wallace E. Maternal and foetal activin A levels: Associations with normal and abnormal labor. Placenta2002;23:570-574.
29.
29. Keelan JA, Marvin KW, Sato TA, et al. Concentrations of activin A, inhibin A and follistatin in human amnion, choriodecidual and placental tissues at term and preterm. J Endocrinol1999;163:99-106.
30.
30. Silver HM, Lambert-Messerlian GM, Star J, Hogan J, Canick JA. Comparison of maternal serum total activin A and inhibin A in normal, preeclamptic, and nonproteinuric gestationally hypertensive pregnancies. Am J Obstet Cynecol1999;180:1131-1137.
31.
31. Lambert-Messerlian GM, Hall JE, Sluss PM, et al. Relatively low levels of dimeric inhibin crculate in men and women with polycystic ovarian syndrome using a 2-site enzyme-linked immunosorbent assay. J Clin Endocrinol Metab1994;79:45-50.
32.
32. Groome NP, Illingworth PJ, O'Brien M, et al. Detection of dimeric inhibin throughout the human menstrual cycle by 2-site enzyme immunoassay. Clin Endocrinol1994;40:717-723.
33.
33. Knight PG, Muttukrishna S, Groome NP. Development and application of a 2-site enzyme immunoassay for the determination of “total” activin-A concentrations in serum and follicular fluid, I Endocrinol1996;148:267-279.
34.
34. Evans LW, Muttukrishna S, Groome NP. Development, validation and application of an ultra-sensitive two-site enzyme immunoassay for total human follistatin. J Endocrinol1998;156:275-282.
35.
35. Robertson PA, Sniderman SH, Laros RK Jr, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986. Am J Obstet Gynecol1992;166:1629-1641.
36.
36. Doyle LW, Rogerson S, Chuang SL, James M, Bowman Ed, Davis PG. Why do preterm infants die in the 1990s?Med J Aust1999;170:528-532.
37.
37. Petraglia F, Di Blasio AM, Florio P, et al. High levels of fetal membrane activin βA and activin IIB mRNAs and augmented concentration of amniotic fluid activin A in women in term and preterm labor. J Endocrinol1997;154:95-101.
38.
38. Scheider-Kolsky M, Manuelpillai U, Waldron K, Dole A, Wallace E. The distribution of activin and activin receptors in gestational tissues across human pregnancy and during labor. Placenta2002:23:294-302.
39.
39. Keelan J, Marvin K, Sato T, Groome N, Mitchell M. Activin A and preterm birth: A re-evaluation (Abstract). Mol Cell Endocrinol2001;180:194-194.
41. Higby K, Xenakis EMJ, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol1993;168:1247-1259.
42.
42. Crowley PA. Antenatal corticosteroid therapy: A meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol1995;173:322-334.
43.
43. Wang E, Woodruff T, Moawad A. Follistatin-free activin A is not associated with preterm birth. Am J Obstet Gynecol2002;186:464-469.
